Dalakas M[au] - Search Results

Year	Number of Results
1978	2
1979	1
1980	5
1981	7
1983	5
1984	7
1985	4
1986	12
1987	8
1988	17
1989	6
1990	10
1991	12
1992	11
1993	9
1994	18
1995	35
1996	19
1997	12
1998	14
1999	10
2000	17
2001	10
2002	10
2003	14
2004	17
2005	13
2006	16
2007	15
2008	13
2009	11
2010	12
2011	14
2012	12
2013	15
2014	10
2015	17
2016	12
2017	5
2018	7
2019	7
2020	13
2021	11
2022	15

1

Inflammatory muscle diseases.

Dalakas MC. Dalakas MC. N Engl J Med. 2015 Apr 30;372(18):1734-47. doi: 10.1056/NEJMra1402225. N Engl J Med. 2015. PMID: 25923553 Free article. Review. No abstract available.

2

Inflammatory myopathies: update on diagnosis, pathogenesis and therapies, and COVID-19-related implications.

Dalakas MC. Dalakas MC. Acta Myol. 2020 Dec 1;39(4):289-301. doi: 10.36185/2532-1900-032. eCollection 2020 Dec. Acta Myol. 2020. PMID: 33458584 Free PMC article. Review.

3

The immunobiology of autoimmune encephalitides.

Alexopoulos H, Dalakas MC. Alexopoulos H, et al. Among authors: dalakas mc. J Autoimmun. 2019 Nov;104:102339. doi: 10.1016/j.jaut.2019.102339. Epub 2019 Oct 11. J Autoimmun. 2019. PMID: 31611142 Review.

4

Polymyositis and dermatomyositis.

Dalakas MC, Hohlfeld R. Dalakas MC, et al. Lancet. 2003 Sep 20;362(9388):971-82. doi: 10.1016/S0140-6736(03)14368-1. Lancet. 2003. PMID: 14511932 Review.

5

Immunotherapy in myasthenia gravis in the era of biologics.

Dalakas MC. Dalakas MC. Nat Rev Neurol. 2019 Feb;15(2):113-124. doi: 10.1038/s41582-018-0110-z. Nat Rev Neurol. 2019. PMID: 30573759 Review.

6

Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Lünemann JD, Nimmerjahn F, Dalakas MC. Lünemann JD, et al. Among authors: dalakas mc. Nat Rev Neurol. 2015 Feb;11(2):80-9. doi: 10.1038/nrneurol.2014.253. Epub 2015 Jan 6. Nat Rev Neurol. 2015. PMID: 25561275 Review.

7

GAD antibody-spectrum disorders: progress in clinical phenotypes, immunopathogenesis and therapeutic interventions.

Tsiortou P, Alexopoulos H, Dalakas MC. Tsiortou P, et al. Among authors: dalakas mc. Ther Adv Neurol Disord. 2021 Mar 30;14:17562864211003486. doi: 10.1177/17562864211003486. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33854562 Free PMC article. Review.

8

Complement in neurological disorders and emerging complement-targeted therapeutics.

Dalakas MC, Alexopoulos H, Spaeth PJ. Dalakas MC, et al. Nat Rev Neurol. 2020 Nov;16(11):601-617. doi: 10.1038/s41582-020-0400-0. Epub 2020 Oct 1. Nat Rev Neurol. 2020. PMID: 33005040 Free PMC article. Review.

9

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies.

Dalakas MC. Dalakas MC. Ther Adv Neurol Disord. 2018 Jan 15;11:1756285617746640. doi: 10.1177/1756285617746640. eCollection 2018. Ther Adv Neurol Disord. 2018. PMID: 29403542 Free PMC article. Review.

10

EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs.

Bertsias GK, Ioannidis JP, Aringer M, Bollen E, Bombardieri S, Bruce IN, Cervera R, Dalakas M, Doria A, Hanly JG, Huizinga TW, Isenberg D, Kallenberg C, Piette JC, Schneider M, Scolding N, Smolen J, Stara A, Tassiulas I, Tektonidou M, Tincani A, van Buchem MA, van Vollenhoven R, Ward M, Gordon C, Boumpas DT. Bertsias GK, et al. Among authors: dalakas m. Ann Rheum Dis. 2010 Dec;69(12):2074-82. doi: 10.1136/ard.2010.130476. Epub 2010 Aug 19. Ann Rheum Dis. 2010. PMID: 20724309

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results